Navigation Links
Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients

es. Taking advantage of the high flexibility of its ImmunodrugTM platform, Cytos Biotechnology has built a pipeline of different ImmunodrugTM candidates in various disease areas, of which 6 are currently in clinical development. The Immunodrug™ candidates are developed both in-house and together with Novartis and Pfizer Animal Health. Founded in 1995 as a spin-off from the Swiss Federal Institute of Technology (ETH) in Zurich, the company is located in Schlieren (Zurich). Currently, the company has 130 employees. Cytos Biotechnology AG has been listed on the SWX Swiss Exchange (SWX:CYTN) since October 2002.

For further information please contact:

Dr. Claudine Blaser
Director Corporate Communications
Phone: +41 44 733 47 20
Fax: +41 44 733 47 18
e-Mail: claudine.blaser@cytos.com
Website: www.cytos.com

This foregoing press release may contain forward-looking statements that include words or phrases such as “aimed at”, “will”, “designed”, “indicate”, “could”, “potential”, “intend” or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any other therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the background of thes
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:5/30/2015)... -- Eisai Inc. announced today the results of its Phase 3 ... primary endpoint evaluating overall survival in patients who had advanced ... soft tissue sarcoma. These data will be presented at the ... Clinical Oncology (ASCO) in Chicago as ... and also in an oral session on Monday, June 1 ...
(Date:5/30/2015)... IRVING, Tex. , May 30, 2015 /PRNewswire/ ... focused on fulfilling the promise of precision medicine, ... studies that demonstrate the utility of Caris Molecular ... in facilitating comparisons between tumors that share histological ... of the American Society of Clinical Oncology (ASCO) ...
(Date:5/29/2015)... OTTAWA , May 29, 2015 /CNW/ - Alliance ... Canada, is recalling the health product Galenic Health ... levels of lead for adolescents and children. The ... limits for children, but within acceptable limits for ... used to relieve digestive upset and disturbances. Alliance ...
Breaking Medicine Technology:Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 2Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 3Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 4Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 5Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 6Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 2Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 3Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 4Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 5Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 6
... SPRINGS, Calif., Feb. 18, 2012 A national coalition ... medication is inviting area residents to safely dispose of ... pharmacies today.   Sponsored by the Collaborating ... the event comes as pain medicine providers prepare to ...
... CHAPEL HILL, N.C., Feb. 17, 2012  Communication channels are ... to seek the ones that drive efficient performance, ... With so many communications options, companies need to ... most effective, and how to best use them. ...
Cached Medicine Technology:National Coalition Holds Prescription Drug Take-back Day in Palm Springs Ahead of Pain Medicine Scientific Meeting 2National Coalition Holds Prescription Drug Take-back Day in Palm Springs Ahead of Pain Medicine Scientific Meeting 3National Coalition Holds Prescription Drug Take-back Day in Palm Springs Ahead of Pain Medicine Scientific Meeting 4Effective Communication Options to Increase Organizational Effectiveness 2
(Date:5/30/2015)... CT (PRWEB) May 30, 2015 "Despite ... do not always get better health outcomes than people ... expensive and not always safe" states author Dr. John ... Health Attitude: Unraveling and Solving the Complexities of ... terms even newcomers to the healthcare policy debate will ...
(Date:5/30/2015)... Twelve of the nation’s leading oncology physicians, ... the 2015 Giants of Cancer Care at ... Company last night. The awardees included medical pioneers selected ... in translational research, gene therapy, immuno-oncology and other groundbreaking ... , Honorees were introduced and celebrated during the third ...
(Date:5/30/2015)... and Montreal, Canada (PRWEB) May 30, 2015 ... process control, and quality assurance, is joining forces with ... offline inspection solutions to the worldwide printing market. ... AVT with a new software engine for its offline ... needs of the printing industry and its varying production ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 You've probably heard ... injury and hearing loss. However, have you found a better ... from Olathe, Kan., have exactly what you need. , They ... wax build-up; dirt and dead, dry skin from the ears. ... cotton swabs or anything on the market today for children ...
(Date:5/30/2015)... 30, 2015 Promising clinical trial results ... Annual Meeting 2015 show activity of the investigational anti-cancer ... specifically against brain metastases and in another case in ... , "I am thrilled to have been able to ... 40s. She didn't have any other great treatment options ...
Breaking Medicine News(10 mins):Health News:"Health Attitude", a new book by Dr. John R. Patrick, explains the American healthcare system, what is wrong with it, and how to fix it. 2Health News:"Health Attitude", a new book by Dr. John R. Patrick, explains the American healthcare system, what is wrong with it, and how to fix it. 3Health News:OncLive’s 2015 Giant of Cancer Care™ Awards Announced 2Health News:OncLive’s 2015 Giant of Cancer Care™ Awards Announced 3Health News:OncLive’s 2015 Giant of Cancer Care™ Awards Announced 4Health News:AVT and Global Vision Collaborate to Offer Cutting-edge Offline Inspection Solutions for Printing Industry 2Health News:AVT and Global Vision Collaborate to Offer Cutting-edge Offline Inspection Solutions for Printing Industry 3Health News:Improved Ear Hygiene Tool Invented by InventHelp Clients (KSC-952) 2Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 2Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 3
... day may perform worse in their study, suggests a new ... link increased TV viewing to academic failure. ,Previous ... in the new study, Jeffrey Johnson of the New York ... habits of 14-year-olds from 678 families in the upper regions ...
... of newborns screened for hearing loss in the US has ... a third of them do not turn up for follow-up ... development that they might never overcome, says author Karl White, ... at Utah State University. ,About 3.8 million newborns ...
... that indicate that subconjunctivally delivered insulin ameliorates degenerative and ... Association for Research in Vision and Ophthalmology (ARVO) 2007 ... take place on Thursday, May 10 from 10:45 a.m. ... Fort Lauderdale/Broward County Convention Center. ,Regular human ...
... of herbal dietary supplements have skyrocketed by 100 percent ... but most people dont consider evidence-based indications before ... published in this months Mayo Clinic Proceedings. ... in accordance with scientific guidelines, according to the article. ...
... the medium- and large-scale genetic differences between humans may soon ... of diseases, according to a paper by Howard Hughes Medical ... May 10, 2007, Nature. The undertaking will help researchers identify ... as much as five to ten percent of the human ...
... study examines the use of tissue-engineered scaffolding made of cartilage ... replace defective cartilage tissue. ,Cartilage cells are ... the body, where new cartilage tissue is grown along the ... ,The procedure was extremely successful in tested mice as ...
Cached Medicine News:Health News:Too Much TV Watching Linked With Poor Academic Performance in Teens 2Health News:Experts Stress Need for Follow-up Evaluation of Children Who Fail Hearing Loss Screening 2Health News:Cataloging the Structural Variations in Human Genetics 2Health News:Cataloging the Structural Variations in Human Genetics 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: